Ingunn Dybedal

  • Senior consultant; MD, PhD
  • +47 23 07 36 01
 

Publications 2024

Baliakas P, Tesi B, Cammenga J, Stray-Pedersen A, Jahnukainen K, Andersen MK, Ågerstam H, Creignou M, Dybedal I, Raaschou-Jensen K, Grønbæk K, Kilpivaara O, Lindberg EH, Wartiovaara-Kautto U (2024)
How to manage patients with germline DDX41 variants: Recommendations from the Nordic working group on germline predisposition for myeloid neoplasms
Hemasphere, 8 (8), e145
DOI 10.1002/hem3.145, PubMed 39139355

Tobiasson M, Pandzic T, Illman J, Nilsson L, Weström S, Ejerblad E, Olesen G, Björklund A, Olsnes Kittang A, Werlenius O, Lorentz F, Rasmussen B, Cammenga J, Weber D, Lindholm C, Wiggh J, Dimitriou M, Moen AE, Yip Lundström L, von Bahr L, Baltzer-Sollander K, Jädersten M, Kytölä S, Walldin G, Ljungman P et al. (2024)
Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation
J Clin Oncol, 42 (12), 1378-1390
DOI 10.1200/JCO.23.01159, PubMed 38232336

Publications 2023

Gotlib J, Castells M, Elberink HO, Siebenhaar F, Hartmann K, Broesby-Olsen S, George TI, Panse J, Alvarez-Twose I, Radia DH, Tashi T, Bulai Livideanu C, Sabato V, Heaney M, Van Daele P, Cerquozzi S, Dybedal I, Reiter A, Pongdee T, Barete S, Ustun C, Schwartz L, Ward BR, Schafhausen P, Vadas P et al. (2023)
Avapritinib versus Placebo in Indolent Systemic Mastocytosis
NEJM Evid, 2 (6), EVIDoa2200339
DOI 10.1056/EVIDoa2200339, PubMed 38320129

Nyquist OE, Dalgaard J, Spetalen S, Torkildsen S, Frøen H, Galteland E, Klungsøyr O, Bergrem A, Vo C, Sørbø H, Eiken B, Lerdal H, Solvang AK, Jensvoll H, Pandzic T, Baliakas P, Dybedal I (2023)
Pathogenic DDX41 variants, possible response predictors to low-dose melphalan in hypo- and normocellular MDS and AML
Br J Haematol, 204 (2), 724-729
DOI 10.1111/bjh.19226, PubMed 38016923

Publications 2022

Krausz M, Uhlmann A, Rump IC, Ihorst G, Goldacker S, Sogkas G, Posadas-Cantera S, Schmidt R, Feißt M, Alsina L, Dybedal I, Recher M, Warnatz K, Grimbacher B (2022)
The ABACHAI clinical trial protocol: Safety and efficacy of abatacept (s.c.) in patients with CTLA-4 insufficiency or LRBA deficiency: A non controlled phase 2 clinical trial
Contemp Clin Trials Commun, 30, 101008
DOI 10.1016/j.conctc.2022.101008, PubMed 36262801

Rasmussen B, Göhring G, Bernard E, Nilsson L, Tobiasson M, Jädersten M, Garelius H, Dybedal I, Grønbaek K, Ejerblad E, Lorenz F, Flogegård M, Marcher CW, Öster Fernström A, Cavelier L, Papaemmanuil E, Ebeling F, Kittang AO, Nørgaard JM, Saft L, Möllgård L, Hellström-Lindberg E (2022)
"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)"
Leukemia, 36 (5), 1436-1439
DOI 10.1038/s41375-022-01537-w, PubMed 35277655

Reiter A, Schwaab J, DeAngelo DJ, Gotlib J, Deininger MW, Pettit KM, Alvarez-Twose I, Vannucchi AM, Panse J, Platzbecker U, Hermine O, Dybedal I, Lin HM, Rylova SN, Ehlert K, Dimitrijević S, Radia DH (2022)
Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis
Blood Adv, 6 (21), 5750-5762
DOI 10.1182/bloodadvances.2022007539, PubMed 35640224

Publications 2021

Egg D, Rump IC, Mitsuiki N, Rojas-Restrepo J, Maccari ME, Schwab C, Gabrysch A, Warnatz K, Goldacker S, Patiño V, Wolff D, Okada S, Hayakawa S, Shikama Y, Kanda K, Imai K, Sotomatsu M, Kuwashima M, Kamiya T, Morio T, Matsumoto K, Mori T, Yoshimoto Y, Dybedal I, Kanariou M et al. (2021)
Therapeutic options for CTLA-4 insufficiency
J Allergy Clin Immunol, 149 (2), 736-746
DOI 10.1016/j.jaci.2021.04.039, PubMed 34111452

Gotlib J, Reiter A, Radia DH, Deininger MW, George TI, Panse J, Vannucchi AM, Platzbecker U, Alvarez-Twose I, Mital A, Hermine O, Dybedal I, Hexner EO, Hicks LK, Span L, Mesa R, Bose P, Pettit KM, Heaney ML, Oh ST, Sen J, Lin HM, Mar BG, DeAngelo DJ (2021)
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial
Nat Med, 27 (12), 2192-2199
DOI 10.1038/s41591-021-01539-8, PubMed 34873345

Wedge E, Hansen JW, Dybedal I, Creignou M, Ejerblad E, Lorenz F, Werlenius O, Ungerstedt J, Holm MS, Nilsson L, Kittang AO, Antunovic P, Rohon P, Andersen MK, Papaemmanuil E, Bernard E, Jädersten M, Hellström-Lindberg E, Grønbæk K, Ljungman P, Friis LS (2021)
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population
Transplant Cell Ther, 27 (12), 991.e1-991.e9
DOI 10.1016/j.jtct.2021.08.028, PubMed 34500124

Publications 2020

Grønvold B, Ali MM, Remberger M, Mattsson J, Egeland T, Lundin KU, Myhre AE, Abrahamsen IW, Heldal D, Dybedal I, Tjønnfjord GE, Fløisand Y, Gedde-Dahl T (2020)
HLA-DPB1 mismatch reduce relapse and improve survival in T-cell replete unrelated donor allogeneic stem cell transplantation
Bone Marrow Transplant, 55 (8), 1658-1661
DOI 10.1038/s41409-020-0827-3, PubMed 32054997

Remberger M, Grønvold B, Ali M, Mattsson J, Egeland T, Lundin KU, Myhre A, Abrahamsen I, Heldal D, Dybedal I, Tjønnfjord GE, Gedde-Dahl T, Fløisand Y (2020)
The CD34+ Cell Dose Matters in Hematopoietic Stem Cell Transplantation with Peripheral Blood Stem Cells from Sibling Donors
Clin Hematol Int, 2 (2), 74-81
DOI 10.2991/chi.d.200221.001, PubMed 34595446

Publications 2019

Baliakas P, Tesi B, Wartiovaara-Kautto U, Stray-Pedersen A, Friis LS, Dybedal I, Hovland R, Jahnukainen K, Raaschou-Jensen K, Ljungman P, Rustad CF, Lautrup CK, Kilpivaara O, Kittang AO, Grønbæk K, Cammenga J, Hellström-Lindberg E, Andersen MK (2019)
Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up
Hemasphere, 3 (6), e321
DOI 10.1097/HS9.0000000000000321, PubMed 31976490

Johansen S, Helgeland L, Vetti N, Dybedal I, Reikvam H (2019)
A man in his seventies with back pain, gastrointestinal symptoms and rash
Tidsskr Nor Laegeforen, 139 (15)
DOI 10.4045/tidsskr.18.0819, PubMed 31642632

Johansen S, Helgeland L, Vetti N, Dybedal I, Reikvam H (2019)
A man in his 70s with back pain, abdominal pain and rash
Tidsskr. Nor. Laegeforen., 139 (15), 1477-1481

Publications 2018

Habberstad AH, Tran HTT, Randen U, Spetalen S, Dybedal I, Tjønnfjord GE, Dahm AEA (2018)
Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report
J Med Case Rep, 12 (1), 105
DOI 10.1186/s13256-018-1663-6, PubMed 29685167

Navarro-Fernández J, Eugenia de la Morena-Barrio M, Martínez-Alonso E, Dybedal I, Toderici M, Bohdan N, Miñano A, Heimdal K, Abildgaard U, Martínez-Menárguez JÁ, Corral J, Vicente V (2018)
Biochemical and cellular consequences of the antithrombin p.Met1? mutation identified in a severe thrombophilic family
Oncotarget, 9 (69), 33202-33214
DOI 10.18632/oncotarget.26059, PubMed 30237862

Schwab C, Gabrysch A, Olbrich P, Patiño V, Warnatz K, Wolff D, Hoshino A, Kobayashi M, Imai K, Takagi M, Dybedal I, Haddock JA, Sansom DM, Lucena JM, Seidl M, Schmitt-Graeff A, Reiser V, Emmerich F, Frede N, Bulashevska A, Salzer U, Schubert D, Hayakawa S, Okada S, Kanariou M et al. (2018)
Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects
J Allergy Clin Immunol, 142 (6), 1932-1946
DOI 10.1016/j.jaci.2018.02.055, PubMed 29729943

Publications 2016

Broesby-Olsen S, Dybedal I, Gülen T, Kristensen TK, Møller MB, Ackermann L, Sääf M, Karlsson MA, Agertoft L, Brixen K, Hermann P, Stylianou E, Mortz CG, Torfing T, Havelund T, Sander B, Bergström A, Bendix M, Garvey LH, Bjerrum OW, Valent P, Bindslev-Jensen C, Nilsson G, Vestergaard H, Hägglund H (2016)
Multidisciplinary Management of Mastocytosis: Nordic Expert Group Consensus
Acta Derm Venereol, 96 (5), 602-12
DOI 10.2340/00015555-2325, PubMed 26694951

Stray-Pedersen A, Sorte HS, Samarakoon P, Gambin T, Chinn IK, Coban Akdemir ZH, Erichsen HC, Forbes LR, Gu S, Yuan B, Jhangiani SN, Muzny DM, Rødningen OK, Sheng Y, Nicholas SK, Noroski LM, Seeborg FO, Davis CM, Canter DL, Mace EM, Vece TJ, Allen CE, Abhyankar HA, Boone PM, Beck CR et al. (2016)
Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders
J Allergy Clin Immunol, 139 (1), 232-245
DOI 10.1016/j.jaci.2016.05.042, PubMed 27577878

Tekpli X, Urbanucci A, Hashim A, Vågbø CB, Lyle R, Kringen MK, Staff AC, Dybedal I, Mills IG, Klungland A, Staerk J (2016)
Changes of 5-hydroxymethylcytosine distribution during myeloid and lymphoid differentiation of CD34+ cells
Epigenetics Chromatin, 9, 21
DOI 10.1186/s13072-016-0070-8, PubMed 27252783

Publications 2014

Husøy MA, Brinch L, Tjønnfjord GE, Gedde-Dahl T, Heldal D, Holme PA, Dybedal I, Kolstad A, Akkök ÇA, Rollag H, Gaustad P, Bergan S, Egeland T, Josefsen D, Kvalheim G, Fløisand Y (2014)
[Allogeneic stem-cell transplantation in adults 1985-2012: results and development]
Tidsskr Nor Laegeforen, 134 (16), 1569-75
DOI 10.4045/tidsskr.13.1415, PubMed 25178233

Woll PS, Kjällquist U, Chowdhury O, Doolittle H, Wedge DC, Thongjuea S, Erlandsson R, Ngara M, Anderson K, Deng Q, Mead AJ, Stenson L, Giustacchini A, Duarte S, Giannoulatou E, Taylor S, Karimi M, Scharenberg C, Mortera-Blanco T, Macaulay IC, Clark SA, Dybedal I, Josefsen D, Fenaux P, Hokland P et al. (2014)
Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo
Cancer Cell, 25 (6), 794-808
DOI 10.1016/j.ccr.2014.03.036, PubMed 24835589

Publications 2013

Mustjoki S, Richter J, Barbany G, Ehrencrona H, Fioretos T, Gedde-Dahl T, Gjertsen BT, Hovland R, Hernesniemi S, Josefsen D, Koskenvesa P, Dybedal I, Markevärn B, Olofsson T, Olsson-Strömberg U, Rapakko K, Thunberg S, Stenke L, Simonsson B, Porkka K, Hjorth-Hansen H, Nordic CML Study Group (NCMLSG) (2013)
Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients
Leukemia, 27 (7), 1520-6
DOI 10.1038/leu.2013.19, PubMed 23328954

Publications 2012

Fløisand Y, Brinch L, Gedde-Dahl T, Tjønnfjord GE, Dybedal I, Holte H, Heldal D, Torfoss D, Aurlien E, Lauritzsen GF, Fosså A, Lehne G, Baggerød E, Kvalheim G, Egeland T, Bishop MR, Fowler DH, Kolstad A (2012)
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation
Bone Marrow Transplant, 47 (12), 1552-7
DOI 10.1038/bmt.2012.63, PubMed 22522568

Publications 2011

Möllgård L, Saft L, Treppendahl MB, Dybedal I, Nørgaard JM, Astermark J, Ejerblad E, Garelius H, Dufva IH, Jansson M, Jädersten M, Kjeldsen L, Linder O, Nilsson L, Vestergaard H, Porwit A, Grønbæk K, Hellström-Lindberg E (2011)
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities
Haematologica, 96 (7), 963-71
DOI 10.3324/haematol.2010.039669, PubMed 21719884

Publications 2009

Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M, Kovanen P, Laurinolli T, Liesveld J, Paquette R, Pinilla-Ibarz J, Rauhala A, Shah N, Simonsson B, Sinisalo M, Steegmann JL, Stenke L, Porkka K (2009)
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
Leukemia, 23 (8), 1398-405
DOI 10.1038/leu.2009.46, PubMed 19295545

Publications 2008

Brinch L, Tjønnfjord G, Gedde-Dahl T, Heldal D, Holme PA, Dybedal I (2008)
[Allogeneic stem cell transplantation in acute myelogenous leukemia]
Tidsskr Nor Laegeforen, 128 (15), 1681-2; author reply 1682
PubMed 18704137

Fløisand Y, Brinch L, Dybedal I, Gedde-Dahl T, Heldal D, Holme PA, Egeland T, Tjønnfjord GE (2008)
[Allogeneic stem cell transplantation in adults with acute lymphoblastic leukaemia]
Tidsskr Nor Laegeforen, 128 (22), 2563-6
PubMed 19023351

Jädersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM, Pascutto C, Porwit A, Cazzola M, Hellström-Lindberg E (2008)
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome
J Clin Oncol, 26 (21), 3607-13
DOI 10.1200/JCO.2007.15.4906, PubMed 18559873

Publications 2005

Jädersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellström-Lindberg E (2005)
Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF
Blood, 106 (3), 803-11
DOI 10.1182/blood-2004-10-3872, PubMed 15840690

Yang L, Dybedal I, Bryder D, Nilsson L, Sitnicka E, Sasaki Y, Jacobsen SE (2005)
IFN-gamma negatively modulates self-renewal of repopulating human hemopoietic stem cells
J Immunol, 174 (2), 752-7
DOI 10.4049/jimmunol.174.2.752, PubMed 15634895

Publications 2004

Dybedal I (2004)
Negative regulators of hematopoietic stem and progenitor cells
In Dissertations at the Faculty of Medicine, NTNU, The Faculty, [Trondheim], 241, 1 b. (flere pag.)
BIBSYS 040969045

Publications 2003

Dybedal I, Yang L, Bryder D, Aastrand-Grundstrom I, Leandersson K, Jacobsen SE (2003)
Human reconstituting hematopoietic stem cells up-regulate Fas expression upon active cell cycling but remain resistant to Fas-induced suppression
Blood, 102 (1), 118-26
DOI 10.1182/blood-2002-07-2286, PubMed 12637333

Hast R, Hellström-Lindberg E, Ohm L, Björkholm M, Celsing F, Dahl IM, Dybedal I, Gahrton G, Lindberg G, Lerner R, Linder O, Löfvenberg E, Nilsson-Ehle H, Paul C, Samuelsson J, Tangen JM, Tidefelt U, Turesson I, Wahlin A, Wallvik J, Winquist I, Oberg G, Bernell P (2003)
No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease
Leukemia, 17 (9), 1827-33
DOI 10.1038/sj.leu.2403035, PubMed 12970783

Hellström-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, Grimfors G, Hesse-Sundin E, Hjorth M, Kanter-Lewensohn L, Linder O, Luthman M, Löfvenberg E, Oberg G, Porwit-MacDonald A, Rådlund A, Samuelsson J, Tangen JM, Winquist I, Wisloff F, Scandinavian MDS Group (2003)
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life
Br J Haematol, 120 (6), 1037-46
DOI 10.1046/j.1365-2141.2003.04153.x, PubMed 12648074

Publications 2001

Bryder D, Ramsfjell V, Dybedal I, Theilgaard-Mönch K, Högerkorp CM, Adolfsson J, Borge OJ, Jacobsen SE (2001)
Self-renewal of multipotent long-term repopulating hematopoietic stem cells is negatively regulated by Fas and tumor necrosis factor receptor activation
J Exp Med, 194 (7), 941-52
DOI 10.1084/jem.194.7.941, PubMed 11581316

Dybedal I, Bryder D, Fossum A, Rusten LS, Jacobsen SE (2001)
Tumor necrosis factor (TNF)-mediated activation of the p55 TNF receptor negatively regulates maintenance of cycling reconstituting human hematopoietic stem cells
Blood, 98 (6), 1782-91
DOI 10.1182/blood.v98.6.1782, PubMed 11535512

Publications 1998

Hellström-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM, Dybedal I, Grimfors G, Kanter-Lewensohn L, Linder O, Luthman M, Löfvenberg E, Nilsson-Ehle H, Samuelsson J, Tangen JM, Winqvist I, Oberg G, Osterborg A, Ost A (1998)
Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients
Blood, 92 (1), 68-75
PubMed 9639501

Publications 1997

Dybedal I, Guan F, Borge OJ, Veiby OP, Ramsfjell V, Nagata S, Jacobsen SE (1997)
Transforming growth factor-beta1 abrogates Fas-induced growth suppression and apoptosis of murine bone marrow progenitor cells
Blood, 90 (9), 3395-403
PubMed 9345022

Publications 1996

Rusten LS, Dybedal I, Blomhoff HK, Blomhoff R, Smeland EB, Jacobsen SE (1996)
The RAR-RXR as well as the RXR-RXR pathway is involved in signaling growth inhibition of human CD34+ erythroid progenitor cells
Blood, 87 (5), 1728-36
PubMed 8634418

Publications 1995

Dybedal I, Jacobsen SE (1995)
Transforming growth factor beta (TGF-beta), a potent inhibitor of erythropoiesis: neutralizing TGF-beta antibodies show erythropoietin as a potent stimulator of murine burst-forming unit erythroid colony formation in the absence of a burst-promoting activity
Blood, 86 (3), 949-57
PubMed 7542505

Dybedal I, Larsen S, Jacobsen SE (1995)
IL-12 directly enhances in vitro murine erythropoiesis in combination with IL-4 and stem cell factor
J Immunol, 154 (10), 4950-5
PubMed 7537295

Publications 1994

Lamvik J, Dybedal I, Hammerstrøm J, Waage A (1994)
Acute leukemia in middle Norway 1984-88
Leuk Lymphoma, 16 (1-2), 65-71
DOI 10.3109/10428199409114141, PubMed 7696933

Publications 1993

Hellström-Lindberg E, Birgegård G, Carlsson M, Carneskog J, Dahl IM, Dybedal I, Grimfors G, Merk K, Tangen JM, Winqvist I (1993)
A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes
Leuk Lymphoma, 11 (3-4), 221-8
DOI 10.3109/10428199309086999, PubMed 7505147

Publications 1990

Dybedal I, Lamvik J (1990)
[Streptococcus viridans and respiratory failure in acute leukemia]
Tidsskr Nor Laegeforen, 110 (2), 213-6
PubMed 2300957

Dybedal I, Lamvik J (1990)
Warfarin as a probable cause of haemolytic anaemia
Thromb Haemost, 63 (1), 143
PubMed 2339352

Publications 1989

Dybedal I, Lamvik J (1989)
Respiratory insufficiency in acute leukemia following treatment with cytosine arabinoside and septicemia with streptococcus viridans
Eur J Haematol, 42 (4), 405-6
PubMed 2721663

Page visits: 10440